Petar M Seferović1,2, Panagiotis Vardas3,4, Ewa A Jankowska5, Aldo P Maggioni6, Adam Timmis7, Ivan Milinković1,8, Marija Polovina1,8, Chris P Gale9,10,11, Lars H Lund12, Yuri Lopatin13, Mitja Lainscak14,15, Gianluigi Savarese12, Radu Huculeci4, Dzianis Kazakiewicz4, Andrew J S Coats16. 1. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 2. Serbian Academy of Sciences and Arts, Belgrade, Serbia. 3. Hygeia Heart Sector, Hygeia Group of Hospitals, Athens, Greece. 4. European Society of Cardiology Health Policy Unit, European Heart Health Institute, European Heart Agency, Brussels, Belgium. 5. Department of Heart Diseases, Wroclaw Medical University, and Centre for Heart Diseases, University Hospital, Wroclaw, Poland. 6. ANMCO Research Center, Heart Care Foundation, Florence, Italy. 7. Queen Mary University London, London, UK. 8. Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia. 9. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. 10. Leeds Institute for Data Analytics, University of Leeds, Leeds, UK. 11. Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 12. Department of Medicine, Karolinska Institute, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden. 13. Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russia. 14. Department of Internal Medicine, and Department of Research and Education, General Hospital Murska Sobota, Murska Sobota, Slovenia. 15. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 16. Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy.
Abstract
AIMS: The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) developed the HFA Atlas to provide a contemporary description of heart failure (HF) epidemiology, resources, reimbursement of guideline-directed medical therapy (GDMT) and activities of the National Heart Failure Societies (NHFS) in ESC member countries. METHODS AND RESULTS: The HFA Atlas survey was conducted in 2018-2019 in 42 ESC countries. The quality and completeness of source data varied across countries. The median incidence of HF was 3.20 [interquartile range (IQR) 2.66-4.17] cases per 1000 person-years, ranging from ≤2 in Italy and Denmark to >6 in Germany. The median HF prevalence was 17.20 (IQR 14.30-21) cases per 1000 people, ranging from ≤12 in Greece and Spain to >30 in Lithuania and Germany. The median number of HF hospitalizations was 2671 (IQR 1771-4317) per million people annually, ranging from <1000 in Latvia and North Macedonia to >6000 in Romania, Germany and Norway. The median length of hospital stay for an admission with HF was 8.50 (IQR 7.38-10) days. Diagnostic and management resources for HF varied, with high-income ESC member countries having substantially more resources compared with middle-income countries. The median number of hospitals with dedicated HF centres was 1.16 (IQR 0.51-2.97) per million people, ranging from <0.10 in Russian Federation and Ukraine to >7 in Norway and Italy. Nearly all countries reported full or partial reimbursement of standard GDMT, except ivabradine and sacubitril/valsartan. Almost all countries reported having NHFS or working groups and nearly half had HF patient organizations. CONCLUSIONS: The first report from the HFA Atlas has shown considerable heterogeneity in HF disease burden, the resources available for its management and data quality across ESC member countries. The findings emphasize the need for a systematic approach to the capture of HF statistics so that inequalities and improvements in care may be quantified and addressed.
AIMS: The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) developed the HFA Atlas to provide a contemporary description of heart failure (HF) epidemiology, resources, reimbursement of guideline-directed medical therapy (GDMT) and activities of the National Heart Failure Societies (NHFS) in ESC member countries. METHODS AND RESULTS: The HFA Atlas survey was conducted in 2018-2019 in 42 ESC countries. The quality and completeness of source data varied across countries. The median incidence of HF was 3.20 [interquartile range (IQR) 2.66-4.17] cases per 1000 person-years, ranging from ≤2 in Italy and Denmark to >6 in Germany. The median HF prevalence was 17.20 (IQR 14.30-21) cases per 1000 people, ranging from ≤12 in Greece and Spain to >30 in Lithuania and Germany. The median number of HF hospitalizations was 2671 (IQR 1771-4317) per million people annually, ranging from <1000 in Latvia and North Macedonia to >6000 in Romania, Germany and Norway. The median length of hospital stay for an admission with HF was 8.50 (IQR 7.38-10) days. Diagnostic and management resources for HF varied, with high-income ESC member countries having substantially more resources compared with middle-income countries. The median number of hospitals with dedicated HF centres was 1.16 (IQR 0.51-2.97) per million people, ranging from <0.10 in Russian Federation and Ukraine to >7 in Norway and Italy. Nearly all countries reported full or partial reimbursement of standard GDMT, except ivabradine and sacubitril/valsartan. Almost all countries reported having NHFS or working groups and nearly half had HF patient organizations. CONCLUSIONS: The first report from the HFA Atlas has shown considerable heterogeneity in HF disease burden, the resources available for its management and data quality across ESC member countries. The findings emphasize the need for a systematic approach to the capture of HF statistics so that inequalities and improvements in care may be quantified and addressed.
Authors: Jan-Per Wenzel; Julius Nikorowitsch; Ramona Bei der Kellen; Christina Magnussen; Renate Bonin-Schnabel; Dirk Westermann; Raphael Twerenbold; Paulus Kirchhof; Stefan Blankenberg; Benedikt Schrage Journal: ESC Heart Fail Date: 2022-04-20
Authors: Lorenzo Stretti; Dauphine Zippo; Andrew J S Coats; Markus S Anker; Stephan von Haehling; Marco Metra; Daniela Tomasoni Journal: ESC Heart Fail Date: 2021-12-16